Bristol-myers Squibb Compnay

Junqing Guo

William John Pitts

Steven H Spergel

Amy C Hart

Carolyn Diane Dzierba

Jie Chen

Guanglin Luo

John E Macor

Sing-Yuen Sit

Scott Hunter Watterson

Jianliang Shi

James Kempson

Jagabandhu Das

Joseph Barbosa

Stephen T Wrobleski

John T Hynes

Yong-Jin Wu

Bin Jiang

Hong Wu

Bingwei Vera Yang

Brian Lee Venables

Shuqun Lin

Michael E Mertzman

Murugaiah Andappan Murugaiah Subbaiah

Jingwu Duan

Michael G Yang

John S Tokarski

Zili Xiao

David Bertil Frennesson

Zhonghui Lu

Charles Malcolm Langevine

Lidia M Doweyko

Gregory D Brown

Matthew Reiser Patton

Xirui Hu

Harold A Mastalerz

Zhizhen Barbara Zheng

Marianne Carlsen

Hua Gong

Jason M Guernon

Marco Dodier

Carolyn A Weigelt

Claude Quesnelle

Michael C Mertzman

Charles M Langevine

Das Jagabandhu

Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

Indazole carboxamides as kinase inhibitors

Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, (I) are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

1H-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (RIPK1)

Compounds having formula (I)-(IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

Aminotriazolopyridines as kinase inhibitors

Triazolopyridinyl compounds as kinase inhibitors

The disclosure relates to compounds of formula I which are useful as kinase modulators including RIPK 1 modulation. The disclosure also provides methods of making and using the compounds for example in treatments related to necrosis or inflammation as well as other indications. 

Aminopyrrolotriazines as kinase inhibitors

Compounds having formula (I) (IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein: (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX). 

Compounds having Formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK3 modulation. All the variables defined herein. 

Substituted dihydro-1H-pyrrolo[3,2-c]pyridin-4(5H)-ones as RIPK3 inhibitors

Disclosed are compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases. 

Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases

The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases. 

Disclosed are compounds of Formula (I), and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases. 

The present invention provides for tricyclic compounds having the formula (I), wherein R, R, R, R, R, and Rare as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.

[object Object]

Fused heterocylic compounds of the following Formula wherein R, R, R, Z, Jand Jare described herein, and analogs thereof are provided which are useful in treating leukocyte activation-associated disorders.

Fused heterocyclic compounds and use thereof

Growing community of inventors

Princeton, NJ, United States of America

Junqing Guo